ITPP

The mechanism of ITPP is elegant and narrow. Hemoglobin inside a red blood cell exists in equilibrium between a high-oxygen-affinity R-state (relaxed, binds O2 tightly) and a low-oxygen-affinity T-state (tense, releases O2). Under normal physiology, a small molecule called 2,3-bisphosphoglycerate (2,3-BPG) sits in the central cavity of hemoglobin and stabilizes the T-state. That is why red blood cells with high 2,3-BPG concentrations — such as those generated during altitude acclimatization — offload more oxygen at a given partial pressure than cells with low 2,3-BPG.

ITPP was engineered specifically to mimic and exceed 2,3-BPG's stabilization of the T-state. Its six phosphate groups give it a charge profile even more negative than 2,3-BPG, and it binds the same central cavity with higher avidity. Once inside the red blood cell and bound to hemoglobin, ITPP forces a measurable right-shift of the oxygen dissociation curve — typically quantified as an increase in P50, the partial pressure of oxygen at which hemoglobin is 50% saturated. A higher P50 means hemoglobin needs a higher PO2 to stay saturated, which is another way of saying oxygen drops off sooner as blood passes through tissue.

The critical question is how ITPP crosses the red blood cell membrane. Free 2,3-BPG cannot cross it at all — red cells make their own internally. ITPP is believed to cross via a combination of passive diffusion across perturbed membranes in oxidatively stressed cells and facilitated entry under conditions of hypoxia. Once inside, it is not efficiently effluxed, so the effect persists for the lifespan of the red blood cell carrying it (weeks, in theory). In practice, pharmacokinetic modeling from the [Biolo et al. 2009 preclinical work] and [Kieda et al. 2013 tumor oxygenation study] suggests the right-shift in P50 after a single IV dose persists for several days and progressively declines as unmodified red cells are replaced.

Downstream consequences extend beyond simple oxygen delivery. Multiple groups have reported that ITPP-treated animals show:

• Reduced tumor hypoxia (measured by pimonidazole staining, HIF-1α reduction), which in principle re-sensitizes tumors to radiotherapy and oxygen-dependent chemotherapy
• Improved cardiac function in failing hearts (Biolo 2009 — ITPP restored exercise tolerance in a rat congestive heart failure model)
• Attenuation of tumor metastasis in murine melanoma and pancreatic cancer models, hypothesized to occur via normalization of the hypoxic tumor niche that drives invasive phenotypes
• Potential benefit in sickle cell disease via destabilization of HbS polymer formation (preclinical only)

The mechanism is not erythropoietin-like. ITPP does not increase red cell count or hemoglobin concentration. It changes the behavior of existing hemoglobin. That distinction matters both pharmacologically and from an anti-doping detection standpoint — ITPP is detectable on specific assays that target inositol pyrophosphate signatures, not by the hemoglobin-count tests used to catch EPO abuse.

ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues. It was developed in the mid-2000s by Claude Nicolau and collaborators working out of Tufts University and the French biotech NormOxys, with the stated goal of creating an oral or injectable drug that could mimic what the body's own 2,3-bisphosphoglycerate (2,3-BPG) does inside red blood cells — only longer-acting and more potent. The molecule was designed by phosphorylating the inositol ring until it carried six phosphate groups arranged as three pyrophosphate units, giving it a negative charge density high enough to penetrate the erythrocyte membrane and bind the central cavity of hemoglobin at the same allosteric site 2,3-BPG uses.

ITPP is classified as a right-shifter of the oxygen–hemoglobin dissociation curve. In plain language, that means a hemoglobin molecule carrying ITPP lets go of its oxygen more easily than hemoglobin alone. Under ordinary conditions, that is a problem — oxygen dropping off too early would starve the brain and cardiac muscle — but in specific pathological states where tissue is hypoxic (cancerous tumors, ischemic heart muscle, sickled erythrocytes, emphysematous lung), the extra unloading pressure can push oxygen into compartments that were previously starved. Preclinical and early clinical work has focused on exactly those states.

In the research body-hacking community, ITPP entered the conversation because of its theoretical endurance-improving properties — the same thing that made it attractive as a heart-failure drug made it attractive to dopers. It became notorious around 2011–2013 after French racehorse trainers were accused of injecting thoroughbreds with ITPP to extend their aerobic capacity; the horse-doping story accelerated the compound's visibility and also shifted how regulators catalogued it. The World Anti-Doping Agency (WADA) added ITPP to its S2 "hormones and metabolic modulators" class, and most major equine and human sport regulators now explicitly test for it. If you are a tested athlete, assume ITPP will cost you your career.

This entry takes the position that ITPP is a research compound with intriguing preclinical data, zero human safety record outside small company-sponsored trials, no approved medical indication, and a banned-substance designation in sport. It covers mechanism, the small amount of real human data that exists, the doping chapter, practical considerations for readers who insist on engaging with it, and the overwhelming reasons most people should leave it alone. For related oxygen-delivery–adjacent interventions, see EPO and tissue-protective fragments, mitochondrial uncouplers, and metabolic exercise mimetics.

IUPAC Name

myo-Inositol trispyrophosphate

CAS Number

3615-82-5

Molecular Formula

C6H18O24P6

Molecular Mass

660.03 g/mol

Unlock the dosing protocols

Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

• Beginner, intermediate and advanced protocols
• Reconstitution and handling notes
• Stacking notes
• Additional dosage notes

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in

Unlock the research summary

Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

• A summary of the key research
• Safety and side effects
• A link to the PubMed results

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in

Interaction Matrix

Related Compounds

Disguised Alpha

$119.99($0.030/mg)

Data Completeness

COA Verification

Research Volume